SciRhom's Groundbreaking Series A Financing
July 12, 2024, 9:45 pm
SciRhom, a Munich-based biopharmaceutical company, recently secured a whopping EUR 63 million in Series A funding. The round was co-led by top investors like Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Partners, with new investor Bayern Kapital and existing backers High-Tech Gründerfonds (HTGF) and PhiFund Ventures from New York also joining in.
This injection of capital will propel SciRhom's mission to revolutionize autoimmune disorder treatment with their innovative iRhom2-targeting therapies. The company's lead antibody program, SR-878, is set to enter clinical development after positive preclinical data in rheumatoid arthritis and inflammatory bowel disease models.
With a stellar leadership team including Dr. Jens Ruhe, Dr. Jan Poth, and Dr. Matthias Schneider at the helm, SciRhom is poised to make a significant impact in the field of autoimmune medicine. The company's strategic approach to targeting iRhom2 promises a transformative effect on patients suffering from autoimmune diseases.
The backing of a high-caliber international consortium of investors and the support of existing shareholders demonstrate the industry's confidence in SciRhom's potential. The company's dedication to rigorous science and cutting-edge research positions them as a frontrunner in the biopharmaceutical landscape.
As SciRhom gears up to initiate their first clinical study in Austria, the future looks bright for this trailblazing company. With a focus on driving innovation and delivering much-needed therapeutic options to patients, SciRhom is set to redefine the treatment of autoimmune disorders.
For more information on SciRhom and their groundbreaking work in autoimmune medicine, visit www.SciRhom.com.
This injection of capital will propel SciRhom's mission to revolutionize autoimmune disorder treatment with their innovative iRhom2-targeting therapies. The company's lead antibody program, SR-878, is set to enter clinical development after positive preclinical data in rheumatoid arthritis and inflammatory bowel disease models.
With a stellar leadership team including Dr. Jens Ruhe, Dr. Jan Poth, and Dr. Matthias Schneider at the helm, SciRhom is poised to make a significant impact in the field of autoimmune medicine. The company's strategic approach to targeting iRhom2 promises a transformative effect on patients suffering from autoimmune diseases.
The backing of a high-caliber international consortium of investors and the support of existing shareholders demonstrate the industry's confidence in SciRhom's potential. The company's dedication to rigorous science and cutting-edge research positions them as a frontrunner in the biopharmaceutical landscape.
As SciRhom gears up to initiate their first clinical study in Austria, the future looks bright for this trailblazing company. With a focus on driving innovation and delivering much-needed therapeutic options to patients, SciRhom is set to redefine the treatment of autoimmune disorders.
For more information on SciRhom and their groundbreaking work in autoimmune medicine, visit www.SciRhom.com.